Analytical Data
-
Gene name
CXCL2
- Application
-
Alternative Names
CXCL2；GRO2；GROB；MIP2A;C-X-C motif chemokine 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P19875
-
Expression Region
35-107aa
-
AA Sequence
APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNGQKA CLNPASPMVKKIIEKMLKNGKSN
-
Molecular Weight
8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CXCL2, also known as chemokine (C-X-C motif) ligand 2, is a member of the CXC chemokine family that plays a crucial role in mediating inflammatory responses and recruiting immune cells to sites of tissue injury or infection. It is primarily produced by various cell types, including macrophages, fibroblasts, and endothelial cells, in response to pro-inflammatory stimuli. Given its significant involvement in inflammation, CXCL2 has attracted attention for its potential implications in various diseases, including cancer, autoimmune disorders, and chronic inflammatory conditions. Research has shown that CXCL2 can promote angiogenesis and tumor progression, making it a target for therapeutic intervention. The study of recombinant CXCL2 proteins allows for a deeper understanding of the chemokine's structure-function relationship and its role in cellular signaling pathways. By generating recombinant CXCL2, researchers can investigate its biological activities, such as leukocyte attraction, proliferation, and activation, under controlled experimental conditions. This not only aids in elucidating the underlying mechanisms of disease processes but also opens avenues for developing novel therapeutic strategies, including antagonists that inhibit its receptor interactions. Furthermore, the characterization of CXCL2’s role in various cellular contexts, such as cancer microenvironments or autoimmune settings, may provide insights into how modulation of this chemokine could enhance treatment efficacy or reduce adverse inflammatory responses. Overall, the research surrounding CXCL2 recombinant proteins represents a critical intersection of immunology, oncology, and therapeutic development, with the potential to yield significant advancements in the understanding and treatment of diseases characterized by dysregulated inflammatory responses.
